Superiority data in DES – are all stents non-inferior?

In the field of drug eluting stents, we have grown used to non-inferiority studies. Two recent publications highlight that one stent may offer real clinical benefits over other contemporary DES. Listen to the trial investigators talk about these two new studies with the potential to change our understanding of the DES landscape. 

“The history of drug eluting stents has taught us that we cannot really talk about class effect when we are addressing the results of one single drug eluting stent, because the DES is unique in that it has a specific platform, polymer, and drug. Therefore, if some results apply to one kind of drug eluting stent, they do not necessarily apply to DES that have some similar components.” Dr. Tullio Palmerini

BIOSTEMI RCT  is the first direct comparison between two newer generation DES in patients with acute ST-segment elevation myocardial infarction (STEMI). Learn about the superiority of Orsiro in STEMI  regarding Target Lesion Failure at 24 months.

The Network Meta-Analysis  on Target Lesion Failure With Current Drug-Eluting Stents conducted by Taglieri et. al. analyzed 99’039 patients in 77 randomized controlled trials (RCT) comparing Orsiro and 9 other currently used DES. See the key learnings and find out more about Orsiro having the highest probability (70.8%) to rank as the best stent, based on SUCRA (Surface Under the Cumulative Ranking Curve) score.

Dr. Juan F. Iglesias (Co-Principal Investigator of the BIOSTEMI RCT, Geneva University Hospitals, Geneva, Switzerland), presents the clinical data results at 24 months and speaks about the superiority in STEMI patients and its benefits for Orsiro DES. 

Dr. Tullio Palmerini (Principal Investigator of the Taglieri et a. Network Meta-Analysis, Policlinico S. Orsola, Bologna, Italy) presents the outcome of the recent network meta-analysis on Target Lesion Failure With Current Drug-Eluting Stents . 

Dr. David Kandzari reviews the long-term outcomes of the BIOFLOW-V randomized controlled trial, comparing the outcomes of Orsiro ultrathin-strut DES to the Xience thin-strut DES. As principal investigator, he shares his insights from the trial and its implications to everyday practice.

Intended for healthcare professionals only. This program is supported by BIOTRONIK. Views and opinions expressed in the program belong to the authors and speakers.  Allied Health Professionals